Fig. 5.

Pharmacological inhibition of JAK2, JNK, c-ABL, and SRC reduces levels of P-STAT3 in bleomycin-challenged mice. a–c a Representative images with b quantification of immunofluorescence stainings and c western blot analyses with quantification of P-STAT3 in the skin of bleomycin-challenged mice treated with the JAK2 inhibitor TG101209, the JNK inhibitor CC-930, c-ABL inhibitor imatinib mesylate, or the SRC inhibitor SU6656. Control mice injected with NaCl and bleomycin-challenged receiving vehicle treatment served as controls. N ≥ 4 mice and 3 technical replicates per group for all experiments. Expected band size for P-STAT3 and STAT3 are 79 kDa (lower faint band) and 86 kDa (higher intense band) and the ladder represents 100 kDa. Beta-actin (expected molecular weight/size 42 kDa) is shown by ladder at 40 kDa. Magnifications of 200-fold and 1000-fold are shown for all immunofluorescence stainings. Horizontal scale bar, 100 μm. Results are shown as median ± interquartile range (IQR). Significance was determined by Mann–Whitney test, as compared to sham-treated or bleomycin-challenged mice, respectively. *P < 0.05; **P < 0.01, ***P < 0.001